










# BeiGene Product Portfolio and Pipeline

Three Marketed Products in China, Three Late-Stage Assets, and Five Early-Stage Clinical Assets

 Global

 China

|                            | ASSETS   | PROGRAMS (MECHANISMS)               | CLINICAL TRIALS                      |                     |                     |               |  | LEAD INDICATIONS  | COMMERCIAL RIGHTS   |
|----------------------------|--|-------------------------------------|--------------------------------------|---------------------|---------------------|---------------|--|---|---|
|                            |  |                                     | DOSE ESC. PH1a                       | DOSE EXPANSION PH1b | DOSE EXPANSION PH2* | PIVOTAL PH2** | PIVOTAL PH3  |   |   |
| Internally-Developed       | zanubrutinib<br><i>(BTK)</i>                       | monotherapy                         |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>R/R MCL (NDA accepted)</li> <li>R/R CLL/SLL, WM</li> <li>WM, 1L CLL/SLL</li> <li>R/R FL</li> </ul>   |  Global              |
|                            |  | GAZYVA® combo ( <i>CD20</i> )       |                                      |                     |                     |               |  |   |   |
|                            | tislelizumab<br><i>(PD-1)</i>                      | monotherapy                         |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>R/R HL (NDA accepted)</li> <li>2L+ UC (pivotal Ph2)</li> <li>2L NSCLC, 1L HCC, 2L ESCC</li> <li>2L/3L HCC</li> <li>R/R NK/T-cell lymphoma</li> <li>1L Sq NSCLC, 1L Non-Sq NSCLC</li> </ul> | Global (heme malignancies)<br>Asia ex-Japan (solid tumors) <sup>1</sup>                                 |
|                            |  | chemo combo ( <i>Chemo</i> )        |                                      |                     |                     |               |  |   |   |
|                            |  | pamiparib combo ( <i>PARP</i> )     |                                      |                     |                     |               |  |   |   |
|                            |  | zanubrutinib combo ( <i>BTK</i> )   |                                      |                     |                     |               |  |   |   |
|                            | pamiparib<br><i>(PARP)</i>                         | monotherapy                         |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>Solid tumors</li> <li>3L gBRCA+ ovarian cancer</li> <li>2L platinum-sensitive ovarian cancer maintenance</li> <li>1L platinum-sensitive gastric cancer maintenance</li> </ul>              |  Global <sup>2</sup> |
|                            |  | TMZ combo ( <i>Chemo</i> )          |                                      |                     |                     |               |  |   |   |
|                            |  | RT/TMZ combo ( <i>RT/Chemo</i> )    |                                      |                     |                     |               |  |   |   |
|                            | lifirafenib<br><i>(RAF Dimer)</i>                  | monotherapy                         |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>B-Raf- or K-RAS/N-RAS-mutated solid tumors</li> <li>B-Raf- or K-RAS/N-RAS-mutated solid tumors</li> </ul>  |  Global <sup>2</sup> |
| BGB-A333<br><i>(PD-L1)</i> | monotherapy and tislelizumab combo ( <i>PD-1</i> ) |                                     |                                      |                     |                     |               | <ul style="list-style-type: none"> <li>Solid tumors</li> </ul> |  Global  |   |
| BGB-A425<br><i>(TIM-3)</i> | monotherapy and tislelizumab combo ( <i>PD-1</i> ) | Planned, IND approved               |                                      |                     |                     |               | <ul style="list-style-type: none"> <li>Solid tumors</li> </ul> |  Global  |   |
| In-Licensed                | REVLIMID®  | ( <i>ImiD</i> )                     |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>R/R MM (marketed), NDMM (marketed), R/R NHL (Ph3)</li> </ul>   |  China               |
|                            | ABRAXANE®  | ( <i>albumin-bound paclitaxel</i> ) |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>Breast cancer</li> </ul>   |  China               |
|                            | VIDAZA®  | ( <i>hypomethylating agent</i> )    |                                      |                     |                     |               |  | <ul style="list-style-type: none"> <li>MDS, AML with 20-30% bone marrow blasts, CMMoL</li> </ul>  |  China               |
|                            | avadomide  | ( <i>CC-122, CELMoD</i> )           | Planned (in Ph2 ex-China by Celgene) |                     |                     |               |  | <ul style="list-style-type: none"> <li>NHL</li> </ul>   |  China               |
|                            | sitravatinib                                       | ( <i>multi-kinase inhibitor</i> )   | Planned (in Ph2 ex-China by Mirati)  |                     |                     |               |  | <ul style="list-style-type: none"> <li>NSCLC</li> </ul>   | Asia ex-Japan, AU, NZ <sup>3</sup>  |

\*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. \*\*Confirmatory clinical trials post approval are required for accelerated approvals. \*\*\*REVLIMID® approved as a combination therapy with dexamethasone. 1. Celgene has the right to develop and commercialize tislelizumab in solid tumors in the U.S., EU, Japan and the rest-of-world outside of Asia. 2. Limited collaboration with Merck KGaA. 3. Collaboration with Mirati Therapeutics, Inc.